Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Sept. 11, 2024 – Social media platforms lit up minutes after the FDA announced its authorization of the updated Novavax COVID-19 vaccine right before Labor Day weekend. It was the last of three ...

Novavax NVAX announced that the FDA granted emergency use authorization (EUA) to an updated version of its protein-based COVID-19 vaccine for ... The deal with Sanofi breathes new life into ...

RSV and Meningitis / travel vaccines will be the COVID vaccine developed by Novavax (NVAX) - as I wrote in a recent note on Novavax: By the terms of the deal, Sanofi made a $500m upfront payment ...

The approval was based on non-clinical data that showed Novavax's updated vaccine provides protection ... including revenue recognition of Sanofi Payment, compared to the consensus of $936.38 ...

The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax's COVID shot. The updated vaccine is authorized for use in individuals 12 ...

Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to ...

Friday, the FDA granted Emergency Use Authorization to Novavax Inc.’s (NASDAQ:NVAX) COVID-19 Vaccine, Adjuvanted ... including revenue recognition of Sanofi Payment, compared to the consensus ...

Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to develop ...